Vident Investment Advisory LLC Boosts Position in Jazz Pharmaceuticals PLC (JAZZ)

Vident Investment Advisory LLC boosted its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 1,167.9% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 23,316 shares of the specialty pharmaceutical company’s stock after purchasing an additional 21,477 shares during the period. Vident Investment Advisory LLC’s holdings in Jazz Pharmaceuticals were worth $3,410,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of JAZZ. US Bancorp DE grew its stake in shares of Jazz Pharmaceuticals by 94.4% in the second quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock worth $118,000 after acquiring an additional 368 shares in the last quarter. Russell Investments Group Ltd. grew its stake in shares of Jazz Pharmaceuticals by 9.8% in the second quarter. Russell Investments Group Ltd. now owns 16,576 shares of the specialty pharmaceutical company’s stock worth $2,578,000 after acquiring an additional 1,483 shares in the last quarter. Janney Montgomery Scott LLC acquired a new position in shares of Jazz Pharmaceuticals in the second quarter worth $211,000. World Asset Management Inc grew its stake in shares of Jazz Pharmaceuticals by 1.9% in the second quarter. World Asset Management Inc now owns 1,441 shares of the specialty pharmaceutical company’s stock worth $224,000 after acquiring an additional 27 shares in the last quarter. Finally, Korea Investment CORP grew its stake in shares of Jazz Pharmaceuticals by 436.6% in the second quarter. Korea Investment CORP now owns 22,000 shares of the specialty pharmaceutical company’s stock worth $3,421,000 after acquiring an additional 17,900 shares in the last quarter. Hedge funds and other institutional investors own 91.30% of the company’s stock.

In related news, SVP Iain Mcgill sold 8,000 shares of the business’s stock in a transaction on Friday, November 17th. The shares were sold at an average price of $133.42, for a total value of $1,067,360.00. Following the completion of the sale, the senior vice president now directly owns 28,383 shares of the company’s stock, valued at $3,786,859.86. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $150.00, for a total transaction of $150,000.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 10,352 shares of company stock valued at $1,417,763. 4.30% of the stock is owned by corporate insiders.

Several equities analysts have commented on JAZZ shares. Stifel Nicolaus restated a “buy” rating and issued a $190.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, October 26th. Piper Jaffray Companies set a $177.00 target price on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, October 21st. Zacks Investment Research downgraded shares of Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, November 10th. Royal Bank Of Canada reiterated an “outperform” rating and set a $195.00 target price (down previously from $210.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, November 8th. Finally, Cantor Fitzgerald reiterated a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Tuesday, August 29th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and nineteen have assigned a buy rating to the stock. Jazz Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $181.28.

Shares of Jazz Pharmaceuticals PLC (JAZZ) opened at $138.97 on Friday. Jazz Pharmaceuticals PLC has a 1 year low of $101.37 and a 1 year high of $163.75. The firm has a market cap of $8,083.13, a price-to-earnings ratio of 16.92, a P/E/G ratio of 0.87 and a beta of 0.98. The company has a quick ratio of 2.94, a current ratio of 3.10 and a debt-to-equity ratio of 0.63.

WARNING: “Vident Investment Advisory LLC Boosts Position in Jazz Pharmaceuticals PLC (JAZZ)” was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at https://www.com-unik.info/2017/12/10/vident-investment-advisory-llc-boosts-position-in-jazz-pharmaceuticals-plc-jazz.html.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

What are top analysts saying about Jazz Pharmaceuticals PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Jazz Pharmaceuticals PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit